Inhibrx Expands Oxford Loan to $500M, Draws $100M to Fund Pipeline
INBX has more than doubled off its 52-week low of $20.55.
Summary
Inhibrx amended its loan agreement with Oxford Finance, expanding the facility to $500 million. The company drew $100 million immediately and can access up to $225 million more in $50 million increments at the lenders' discretion. This follows the $75 million debt financing disclosed in the Q1 2026 10-Q, bringing total drawn to $275 million. The capital extends the runway for ozekibart and INBRX-106 ahead of key data readouts, with the BLA for ozekibart already accepted and a PDUFA date set for April 2027. The warrants issued cover 21,457 shares at $93.21, a modest dilution. The financing signals lender confidence in the pipeline and reduces near-term equity risk.
At the time of this announcement, INBX was trading at $91.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $20.55 to $155.29. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.